Overview

Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm

Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Prospective, multicenter, non-comparative, observational program designed to assess the effectiveness of a 2-6 weeks treatment with Duspatalin® 200mg bis in die = twice a day (BID) and changes in quality of life in patients with post-cholecystectomy gastro-intestinal spasms
Details
Lead Sponsor:
Abbott
Collaborator:
Data Matrix
Treatments:
Alverine
Mebeverine